Bank of New York Mellon
AGN

Bank of New York Mellon’s Allergan Inc AGN Stock Holding History

Bank of New York Mellon’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,739,944
Closed -$795M – 4364
2014
Q4 		$795M Sell
3,739,944
-97,548
-3% -$19.4M 0.21% 101
2014
Q3 		$684M Sell
3,837,492
-20,465
-0.5% -$3.4M 0.19% 108
2014
Q2 		$653M Sell
3,857,957
-2,044,803
-35% -$318M 0.18% 115
2014
Q1 		$733M Sell
5,902,760
-127,859
-2% -$15.6M 0.2% 100
2013
Q4 		$670M Buy
6,030,619
+1,499,947
+33% +$143M 0.19% 108
2013
Q3 		$410M Buy
4,530,672
+137,322
+3% +$12.3M 0.12% 173
2013
Q2 		$370M Buy
+4,393,350
New +$456M 0.12% 175

Other funds holding AGN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return
ECM
Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Bank of New York Mellon's AGN Position: Q1 2015 in Review

Bank of New York Mellon sold out of Allergan Inc (AGN) in Q1 2015, closing a stake of 3,739,944 shares — an estimated $795M sold.

Bank of New York Mellon first reported a position in AGN in Q2 2013 and held it in 7 quarters. The position peaked at $795M in Q4 2014. 5 funds tracked by Wall St. Rank hold AGN as of Q1 2015.

  • Bank of New York Mellon reported no remaining Allergan Inc position as of Q1 2015 after selling out during the quarter.
  • Bank of New York Mellon sold 3,739,944 Allergan Inc shares in Q1 2015, an estimated $795M.
  • Bank of New York Mellon first reported a position in Allergan Inc in Q2 2013 and held it in 7 quarters.
  • Bank of New York Mellon's Allergan Inc position peaked at $795M in Q4 2014.
  • 5 funds tracked by Wall St. Rank held Allergan Inc as of Q1 2015.

Based on Bank of New York Mellon's 13F filing for Q1 2015, filed 13 May 2015.